KEYTRUDA 25 mg/mL concentrate for solution for infusion, FYB206, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion
FYB206-C3-02
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, FYB206, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion for NSCLC is a Phase 3 program (small_molecule) at Formycon AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Formycon AG
- Indication
- NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active